Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)
Taiwan
· Delayed Price · Currency is TWD 131.00
-8.50 (-6.09%)
Mar 9, 2026, 1:30 PM CST
TPE:6919 Revenue
Caliway Biopharmaceuticals had revenue of 13.42M TWD in the quarter ending September 30, 2025, a decrease of -42.32%. This brings the company's revenue in the last twelve months to 34.99M, down -29.99% year-over-year. In the year 2024, Caliway Biopharmaceuticals had annual revenue of 44.43M with 14.13% growth.
Revenue (ttm)
34.99M
Revenue Growth
-29.99%
P/S Ratio
5,803.08
Revenue / Employee
n/a
Employees
n/a
Market Cap
203.05B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pell Bio-Med Technology | 29.99M |
| Lumosa Therapeutics | 35.83M |
| Oneness Biotech | 117.33M |
| Polaris Group | 70.83M |
| Sunmax Biotechnology | 2.00B |
| EirGenix | 936.18M |
| TaiMed Biologics | 607.22M |
| AP Biosciences | 32.25M |